Use of Proteomics for the Diagnosis of a Platelet-related Bleeding Disorder

Inherited Platelet Disorders Clinical Trial

Official title:

Use of Proteomics for the Diagnosis of a Platelet-related Bleeding Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02096523
• Other study ID #: 002714- HMO-CTIL
• Status: Completed
• Phase: N/A
• Start date: November 2016
• Est. completion date: July 2021

Study information

• Verified date: August 2021
• Source: Hadassah Medical Organization
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to identify the platelet defect responsible for the bleeding in families from our inherited platelet disorders Israeli-Palestinian registry. The investigators plan to characterize platelet proteome expression after removing high abundance proteins. The investigators will compare the proteome of sick and healthy members of families with inherited platelet disorders, and identify and validate structural proteins, signaling cascades and biomarkers for detection and diagnosis of unknown platelet disorders. The investigators expect to discover new key findings that allow better understanding of human platelet function and allow better diagnosis and treatment of patients with inherited platelet function disorders.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4
• Est. completion date: July 2021
• Est. primary completion date: January 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 3 Years to 85 Years

Eligibility

Inclusion Criteria:

• History of inherited platelet disorders in the family

Exclusion Criteria:

• none

Related Conditions & MeSH terms

• Blood Coagulation Disorders
• Blood Platelet Disorders
• Disease
• Hemostatic Disorders
• Inherited Platelet Disorders

Intervention

Other:
• Blood collection for platelet protein samples

Locations

Country	Name	City	State
Israel	Hadassah Medical Organization	Jerusalem

Sponsors (1)

Lead Sponsor	Collaborator
Ela Shai

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of proteins that inducate disease	Identify and validate a panel of specific biomarkers candidates	2017-2019 (2 years)
Primary	Levels of detectable platelet proteins	Characterize platelet proteome expression profile	2014-2015 (1 year)
Secondary	Changes in protein expression from sick and healthy platelets	Analysis of platelet proteome of sick and healthy members of families with inherited platelet disorders	2015-2019 (4 years)